Sequence-based design of bioactive small molecules that target precursor microRNAs

N/ACitations
Citations of this article
285Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Oligonucleotides are designed to target RNA using base pairing rules, but they can be hampered by poor cellular delivery and nonspecific stimulation of the immune system. Small molecules are preferred as lead drugs or probes but cannot be designed from sequence. Herein, we describe an approach termed Inforna that designs lead small molecules for RNA from solely sequence. Inforna was applied to all human microRNA hairpin precursors, and it identified bioactive small molecules that inhibit biogenesis by binding nuclease-processing sites (44% hit rate). Among 27 lead interactions, the most avid interaction is between a benzimidazole (1) and precursor microRNA-96. Compound 1 selectively inhibits biogenesis of microRNA-96, upregulating a protein target (FOXO1) and inducing apoptosis in cancer cells. Apoptosis is ablated when FOXO1 mRNA expression is knocked down by an siRNA, validating compound selectivity. Markedly, microRNA profiling shows that 1 only affects microRNA-96 biogenesis and is at least as selective as an oligonucleotide. © 2014 Nature America, Inc. All rights reserved.

Cite

CITATION STYLE

APA

Velagapudi, S. P., Gallo, S. M., & Disney, M. D. (2014). Sequence-based design of bioactive small molecules that target precursor microRNAs. Nature Chemical Biology, 10(4), 291–297. https://doi.org/10.1038/nchembio.1452

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free